Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment
暂无分享,去创建一个
R. Gerli | E. Bartoloni | A. Alunno | P. Gresele | E. Falcinelli | O. Bistoni | G. Cafaro | C. Perricone | S. Cipriani | A. F. Bonifacio | E. Petito | E. Giglio | Maria Chiara Borghi
[1] L. Bertoletti,et al. Platelets as Key Factors in Inflammation: Focus on CD40L/CD40 , 2022, Frontiers in Immunology.
[2] J. Fish,et al. Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment , 2021, Frontiers in Pharmacology.
[3] N. Goswami,et al. Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis , 2021, Journal of clinical medicine.
[4] T. Jenssen,et al. Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis , 2021, PloS one.
[5] B. Kiss,et al. Pharmacological Effects of Methotrexate and Infliximab in a Rats Model of Diet-Induced Dyslipidemia and Beta-3 Overexpression on Endothelial Cells , 2021, Journal of clinical medicine.
[6] H. Sayles,et al. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis , 2021, Annals of the Rheumatic Diseases.
[7] C. Prati,et al. Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review , 2021, Expert review of clinical pharmacology.
[8] Dafeng Yang,et al. Methotrexate attenuates vascular inflammation through an adenosine-microRNA-dependent pathway , 2021, eLife.
[9] G. Fu,et al. Methotrexate Therapy Promotes Cell Coverage and Stability in in-Stent Neointima , 2021, Cardiovascular Drugs and Therapy.
[10] ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.
[11] E. De Robertis,et al. Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients , 2020, Journal of Infection.
[12] J. Tao,et al. Circulating senescent angiogenic T cells are linked with endothelial dysfunction and systemic inflammation in hypertension , 2020, Journal of hypertension.
[13] H. Heerspink,et al. Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor Linagliptin: A subanalysis from a randomized, placebo‐controlled trial (RELEASE study) , 2020, Diabetes, obesity & metabolism.
[14] H. Nie,et al. Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow , 2019, Journal of Translational Medicine.
[15] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[16] M. Manetti,et al. Angiogenic T cells in primary Sjögren's syndrome: a double-edged sword? , 2019, Clinical and experimental rheumatology.
[17] U. Müller-Ladner,et al. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity , 2019, Science Translational Medicine.
[18] P. Libby,et al. Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.
[19] G. Valesini,et al. Microparticles and autophagy: a new frontier in the understanding of atherosclerosis in rheumatoid arthritis , 2018, Immunologic Research.
[20] D. Courvoisier,et al. Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis , 2018, Arthritis care & research.
[21] V. Bojinca,et al. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. , 2018, Experimental and therapeutic medicine.
[22] H. Volk,et al. Circulating endothelial cells as biomarker for cardiovascular diseases , 2018, Research and practice in thrombosis and haemostasis.
[23] A. Mangoni,et al. Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence , 2017, Mediators of inflammation.
[24] S. Agewall,et al. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis , 2017, Arthritis Research & Therapy.
[25] B. Cosmi,et al. Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs. , 2017, Thrombosis research.
[26] X. Bai,et al. Methotrexate improves perivascular adipose tissue/endothelial dysfunction via activation of AMPK/eNOS pathway. , 2017, Molecular medicine reports.
[27] J. Miao,et al. Circulating Angiogenic T Cells and Their Subpopulations in Patients with Systemic Lupus Erythematosus , 2016, Mediators of inflammation.
[28] L. Caminal-Montero,et al. Senescent profile of angiogenic T cells from systemic lupus erythematosus patients , 2016, Journal of leukocyte biology.
[29] T. Huizinga,et al. Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis , 2015, Arthritis Research & Therapy.
[30] R. Gerli,et al. Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren's syndrome: new markers of chronic endothelial damage? , 2015, Rheumatology.
[31] W. Gulliver,et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis , 2015, Annals of the rheumatic diseases.
[32] J. Boyle,et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation , 2014, Annals of the rheumatic diseases.
[33] D. Francisci,et al. Potential anti-inflammatory effects of maraviroc in HIV-positive patients: A pilot study of inflammation, endothelial dysfunction, and coagulation markers , 2014, Scandinavian journal of infectious diseases.
[34] P. López,et al. Angiogenic T cells are decreased in rheumatoid arthritis patients , 2014, Annals of the rheumatic diseases.
[35] D. Francisci,et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients , 2013, Thrombosis and Haemostasis.
[36] Gary S Collins,et al. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2 , 2012, BMJ : British Medical Journal.
[37] L. Jian,et al. Effects of Xinfeng Capsules on Expression of Platelet Granule Membrane Protein 140 and Platelet Cluster of Differentiation 40 Ligand in Peripheral Blood of Adjuvant Arthritis Rats , 2012, International journal of rheumatology.
[38] D. Francisci,et al. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. , 2011, AIDS patient care and STDs.
[39] Emanuela Falcinelli,et al. Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake. , 2011, American journal of physiology. Heart and circulatory physiology.
[40] G. Kitas,et al. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications , 2011, Rheumatology International.
[41] L. Boon,et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. , 2010, Blood.
[42] A. Silman,et al. UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .
[43] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[44] T. Rabelink,et al. Inflammation, vascular injury and repair in rheumatoid arthritis , 2009, Annals of the rheumatic diseases.
[45] M. Verhaar,et al. Endothelial progenitor cell dysfunction in rheumatic disease , 2009, Nature Reviews Rheumatology.
[46] Ju-Young Kim,et al. Identification of a Novel Role of T Cells in Postnatal Vasculogenesis: Characterization of Endothelial Progenitor Cell Colonies , 2007, Circulation.
[47] P. Gresele,et al. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication , 2007, Thrombosis and Haemostasis.
[48] A. Giordano,et al. CD4+CD28− T Lymphocytes Contribute to Early Atherosclerotic Damage in Rheumatoid Arthritis Patients , 2004, Circulation.
[49] Patrick André,et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.
[50] R. Schaeffer,et al. Methotrexate Causes Apoptosis in Postmitotic Endothelial Cells , 2000, Biological research for nursing.
[51] P. Gresele,et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. , 2009, Thrombosis research.
[52] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..